Cargando…
Electrolyte disturbances and acute kidney injury induced by imatinib therapy
Imatinib mesylate is an anticancer agent that selectively inhibits protein kinases involved in the pathophysiology of cancer. It is now the first-line therapy for patients with chronic myeloid leukaemia (CML) and is generally well tolerated. Here, we describe a case of a patient receiving imatinib f...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2009
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4421484/ https://www.ncbi.nlm.nih.gov/pubmed/25949279 http://dx.doi.org/10.1093/ndtplus/sfn188 |